Cargando…
Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
Cardiotoxicity of doxorubicin (DOX) remains an important health concern. DOX cardiotoxicity is cumulative-dose-dependent and begins with the first dose of chemotherapy. No biomarker for presymptomatic detection of DOX cardiotoxicity has been validated. Our hypothesis is that peripheral blood cells (...
Autores principales: | Todorova, Valentina K., Makhoul, Issam, Siegel, Eric R., Wei, Jeanne, Stone, Annjanette, Carter, Weleetka, Beggs, Marjorie L., Owen, Aaron, Klimberg, V. Suzanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973957/ https://www.ncbi.nlm.nih.gov/pubmed/27490685 http://dx.doi.org/10.1371/journal.pone.0160224 |
Ejemplares similares
-
Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
por: Todorova, Valentina K., et al.
Publicado: (2017) -
Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model
por: Todorova, Valentina K., et al.
Publicado: (2012) -
Correction: Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model
por: Todorova, Valentina K., et al.
Publicado: (2013) -
Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer
por: Bauer, Michael A., et al.
Publicado: (2021) -
Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model
por: Todorova, Valentina K., et al.
Publicado: (2020)